PRIME MEDICINE INC COM

The FDA has cleared the IND for PM577a, allowing Prime Medicine to start clinical trials in the U.S. and to build a global phase‑1/2 program alongside an already approved study in New Zealand. PM577a uses prime editing and targets the H1069Q mutation in the ATP7B gene, which accounts for 30–50% of cases in the U.S. and Europe; the treatment is administered as a one‑time intravenous infusion. The open first‑in‑human study will evaluate safety, tolerability, biological activity and efficacy at ascending doses in adults and adolescents; study start is planned for the second half of 2026, with initial data expected in 2027. The company is also developing a follow‑on candidate targeting the R778L mutation, which is common in East Asian populations. » Plus sur de.investing.com

Prime Medicine shares climbed after an arbitration ruling confirmed that the development project PM647 falls under Prime Medicine’s jurisdiction and that Beam has no claim for damages. PM647 uses Prime Medicine’s liver lipid nanoparticle technology to correct the E342K mutation in alpha-1 antitrypsin deficiency. Prime Medicine plans to file an application for clinical testing of PM647 in the third quarter of 2026, with initial clinical data expected in 2027; the company has also received approval for the clinical entry of PM577a. » Plus sur de.investing.com

An arbitration panel ruled that the development rights to PM647 fall within Prime Medicine’s contractual scope; Prime Medicine was not found to have breached the contract and was not ordered to make any payment to Beam Therapeutics. The decision removes the main litigation risk and allows the company to file an application for an investigational product and/or a clinical trial for PM647 in Q3 2026. Initial clinical data are expected in 2027. The news drove the share price significantly higher and complements recent regulatory and analyst-positive signals for Prime Medicine. » Plus sur de.investing.com